Core Points - The document outlines the share repurchase management system of Guangzhou Maipu Regenerative Medicine Technology Co., Ltd, aiming to standardize share repurchase behavior, maintain market order, and protect the rights of investors and the company [1][2]. Group 1: General Principles - The share repurchase management system is established based on various laws and regulations, including the Company Law and Securities Law of the People's Republic of China [1]. - The company must ensure that share repurchases do not harm the legitimate rights and interests of shareholders and creditors, and must establish effective internal control systems [3][4]. Group 2: Conditions for Share Repurchase - The company can repurchase shares under specific circumstances, such as reducing registered capital, employee stock ownership plans, or when the stock price falls below certain thresholds [2][3]. - Conditions for repurchase include the stock being listed for at least six months and the company having no major legal violations in the past year [10]. Group 3: Implementation Procedures - The board of directors must carefully evaluate the company's financial status and ensure that the repurchase plan aligns with the company's actual financial situation [4][27]. - The repurchase plan must include details such as the purpose, method, price range, and funding sources [33][20]. Group 4: Disclosure Requirements - The company must disclose the repurchase plan and any changes to it, ensuring transparency with shareholders and regulatory bodies [36][38]. - Regular updates on the progress of the repurchase must be provided, including the number of shares repurchased and the total amount spent [36][29]. Group 5: Handling of Repurchased Shares - Repurchased shares must be handled according to the disclosed purposes, either being canceled or transferred as per legal requirements [40][46]. - The company must notify creditors if it plans to cancel repurchased shares [18].

General Principles - The implementation rules for the Nomination Committee of Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. aim to standardize the selection and recruitment process for senior management and optimize the composition of the board and senior management [1][2] - The Nomination Committee is established as a specialized working body under the board of directors, responsible for researching selection criteria and procedures for directors and senior management, as well as reviewing their qualifications [1][2] Composition of Members - The Nomination Committee consists of three directors, with independent directors making up more than half of the committee [2][3] - The members are nominated by the chairman, more than half of the independent directors, or one-third of all directors, and elected by the board [2][3] - The committee has a convener who is elected from among the independent directors and approved by the board [2][3] Responsibilities and Authority - The main responsibilities of the Nomination Committee include researching selection criteria for directors and senior management, selecting qualified candidates, and reviewing their qualifications [3][4] - The committee is tasked with proposing nominations or dismissals of directors and hiring or firing senior management, as well as other matters as authorized by the board [3][4] Decision-Making Procedures - The selection process for directors and senior management involves communication with relevant departments, gathering candidate information, and conducting qualification reviews [5][6] - The committee must seek the consent of nominated individuals before considering them as candidates [5][6] Meeting Rules - The Nomination Committee holds meetings as needed, with a requirement for at least two-thirds of members to be present for decisions [6][7] - Decisions are made by majority vote, and meeting records must be kept for at least ten years [6][7] Supplementary Provisions - The implementation rules take effect upon approval by the board and are subject to revision in accordance with national laws and regulations [8]

Group 1 - The board of directors of Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. held its ninth meeting of the third session on May 28, 2025, with all nine directors present [2][3] - The meeting approved the proposal to amend the company's articles of association and related rules to enhance corporate governance and compliance with relevant laws [2][3] - The board also approved the proposal to revise and establish related systems to further improve the company's governance framework [3][4] Group 2 - The company plans to hold its first extraordinary general meeting of shareholders for 2025 on June 13, 2025, to review matters requiring shareholder approval [4] - All proposals passed with unanimous support, with 9 votes in favor and no votes against or abstaining [3][4]

Meeting Information - The company will hold its first extraordinary general meeting of shareholders in 2025 on June 13, 2025 [2][4] - The meeting will be convened by the board of directors of Guangzhou Maipu Regenerative Medicine Technology Co., Ltd. [2][4] - The meeting will be conducted both in-person and via online voting [4][9] Voting Details - The voting period through the Shenzhen Stock Exchange trading system is from 9:15 to 9:25 and 9:30 to 13:00 on June 13, 2025 [2][4] - The online voting can be conducted anytime between 9:15 and 15:00 on the same day [2][4] - Shareholders must choose either in-person or online voting, with the first valid vote being counted in case of duplicate votes [4][9] Attendance and Registration - The record date for shareholders to attend the meeting is June 9, 2025 [4] - Registration for the meeting will take place on June 10, 2025, from 9:00 to 11:30 and 14:00 to 16:30 [8] - Shareholders can authorize others to attend on their behalf, and the authorized person does not need to be a shareholder [4][8] Agenda Items - The meeting will discuss several proposals, including a special resolution that requires approval from more than two-thirds of the voting rights held by attending shareholders [7] - The proposals have been approved by the company's board of directors during its ninth meeting [6][7] Contact Information - For inquiries, shareholders can contact Long Xiaoyan at 020-32296113 or via email at irm@medprin.com [8]

证券代码：301033 证券简称：迈普医学 公告编号：2025-029 广州迈普再生医学科技股份有限公司 第三届董事会第九次会议决议公告 董事会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完 整，没有虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 广州迈普再生医学科技股份有限公司（以下简称"公司"）第三 届董事会第九次会议于 2025 年 5 月 28 日下午 14:30 以现场和通讯相 结合的方式在公司会议室召开。本次会议通知已于 2025 年 5 月 23 日 以邮件的方式发出。会议应出席董事 9 人，实际出席董事 9 人，其中， 袁玉宇先生、郑海莹女士以通讯方式出席会议。本次会议由董事长袁 玉宇先生召集并主持，公司全体董事出席了会议，全体监事、高级管 理人员列席了会议。本次会议的召集、召开和表决程序符合国家有关 法律、行政法规及《广州迈普再生医学科技股份有限公司章程》（以 下简称"《公司章程》"）的规定，会议形成的决议合法有效。 二、董事会会议审议情况 本次会议以记名方式投票表决，审议并通过了以下事项： （一）审议通过《关于修订<公司章程>及相关议事规则的议案》 为进一步完善 ...

回购股份管理制度 MP-CG-031,V2.0 广州迈普再生医学科技股份有限公司 回购股份管理制度 二〇二五年五月 回购股份管理制度 MP-CG-031,V2.0 广州迈普再生医学科技股份有限公司 回购股份管理制度 第一章 总则 第一条 为规范公司回购股份行为，维护证券市场秩序，保护投资者和公司 合法权益，根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中 华人民共和国证券法》（以下简称"《证券法》"）、《关于支持上市公司回购 股份的意见》（以下简称"《意见》"）、《上市公司股份回购规则》（以下简 称"《回购规则》"）、《深圳证券交易所创业板股票上市规则》（以下简称"《上 市规则》"）、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市 公司规范运作》（以下简称"《自律监管指引第 2 号》"）及《深圳证券交易所 上市公司自律监管指引第 9 号——回购股份》（以下简称"《自律监管指引第 9 号》"）等法律、行政法规、规范性文件及《广州迈普再生医学科技股份有限公 司章程》（以下简称"公司章程"）的有关规定，结合公司实际情况，特制定《广 州迈普再生医学科技股份有限公司回购股份管理制度》（以下简称 ...

独立董事专门会议工作制度 MP-CG-029,V2.0 广州迈普再生医学科技股份有限公司 独立董事专门会议工作制度 二〇二五年五月 独立董事专门会议工作制度 MP-CG-029,V2.0 广州迈普再生医学科技股份有限公司 独立董事专门会议工作制度 第一章 总 则 第一条 为进一步规范广州迈普再生医学科技股份有限公司（以下简称"公 司"）独立董事专门会议议事方式和决策程序，促使并保障独立董事有效地履行 其职责，充分发挥独立董事在公司内部治理中的作用。根据《中华人民共和国公 司法》《上市公司独立董事管理办法》等法律、行政法规、规范性文件及《广州 迈普再生医学科技股份有限公司章程》（以下简称《公司章程》）、《广州迈普 再生医学科技股份有限公司独立董事工作制度》有关规定，结合公司实际情况， 制定本工作制度。 第二条 独立董事专门会议是指全部由公司独立董事参加，为履行独立董事 职责专门召开的会议。 第三条 公司应当为独立董事专门会议的召开提供便利和支持，公司指定证 券部、董事会秘书协助独立董事专门会议的召开。 第二章 职责权限 第四条 独立董事对公司及全体股东负有忠实与勤勉义务，应当按照法律、 行政法规、中国证监会规定 ...

董事会提名委员会实施细则 MP-CG-006,V3.0 广州迈普再生医学科技股份有限公司 董事会提名委员会实施细则 二〇二五年五月 董事会提名委员会实施细则 MP-CG-006,V3.0 广州迈普再生医学科技股份有限公司 董事会提名委员会实施细则 第一章 总则 第一条 为规范广州迈普再生医学科技股份有限公司(以下简称"公司")决策和经 营管理层等高级管理人员的选拔和录用程序，优化董事会和高级管理人员的组成结构， 从而进一步完善公司的法人治理结构，根据《中华人民共和国公司法》（以下简称《公 司法》）、《上市公司独立董事管理办法》《上市公司治理准则》《深圳证券交易所上 市公司自律监管指引第 2 号——创业板上市公司规范运作》等法律、行政法规、规范性 文件及《广州迈普再生医学科技股份有限公司章程》(下称"公司章程"）的有关规定， 公司特设立董事会提名委员会，并制定本实施细则。 第二条 董事会提名委员会是董事会设立的专门工作机构，主要负责研究董事和高 级管理人员的选择标准和选择程序，对公司董事和高级管理人员及其任职资格进行遴选、 审核。提名委员会在董事会领导下开展工作，对董事会负责。 董事会提名委员会实施细则 MP- ...

公司章程 广州迈普再生医学科技股份有限公司 章 程 2025 年 5 月 | | | | 第一章 | 总则 | 3 | | --- | --- | --- | | 第二章 | 经营宗旨和范围 | 4 | | 第三章 | 股份 | 5 | | 第一节 | 股份发行 | 5 | | 第二节 | 股份增减和回购 | 6 | | 第三节 | 股份转让 | 8 | | 第四章 | 股东和股东会 | 9 | | 第一节 | 股东的一般规定 | 9 | | 第二节 | 控股股东和实际控制人 | 13 | | 第三节 | 股东会的一般规定 | 14 | | 第四节 | 股东会的召集 | 17 | | 第五节 | 股东会的提案与通知 | 19 | | 第六节 | 股东会的召开 | 21 | | 第七节 | 股东会的表决和决议 | 24 | | 第五章 | 董事和董事会 | 29 | | 第一节 | 董事的一般规定 | 29 | | 第二节 | 董事会 | 34 | | 第三节 | 独立董事 | 42 | | 第四节 | 董事会专门委员会 | 45 | | 第六章 | 高级管理人员与公司激励约束机制 | 48 | | 第一节 | ...

董事会薪酬与考核委员会实施细则 MP-CG-007,V3.0 广州迈普再生医学科技股份有限公司 董事会薪酬与考核委员会实施细则 二〇二五年五月 董事会薪酬与考核委员会实施细则 MP-CG-007,V3.0 广州迈普再生医学科技股份有限公司 董事会薪酬与考核委员会实施细则 第一章 总则 第一条 为进一步健全广州迈普再生医学科技股份有限公司(以下简称"公司")董 事(不包括独立董事)及高级管理人员的薪酬与考核制度，完善公司的法人治理结构，根 据《中华人民共和国公司法》(以下简称《公司法》)、《上市公司独立董事管理办法》《上 市公司治理准则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》等相关法律、行政法规、规范性文件及《广州迈普再生医学科技股份有限公 司章程》(下称"公司章程"）的有关规定，公司特设立董事会薪酬与考核委员会，并制 定本实施细则。 第二条 董事会薪酬与考核委员会是董事会设立的专门工作机构，对董事会负责， 主要负责制定、审核董事和高级管理人员的薪酬方案和考核标准，对董事和高级管理人 员的薪酬、股权激励计划、员工持股计划等向董事会提出建议。 第三条 本细则所称董事是指在本公 ...